https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53526 Wed 28 Feb 2024 15:51:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53973 Wed 24 Jan 2024 15:55:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42037 Wed 17 Aug 2022 12:13:25 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39851 .05). Objective sleep onset latency increased from the Baseline to the Treatment phase in the control (stretching) group (p = .042). In contrast, the Cycling group exhibited improvements in sleep duration (p = .008) and sleep efficiency (p = .023) during the Treatment phase compared to the Baseline phase. Cycling also increased sleep duration (p = .005), decreased average wake bout (p = .040) and tended to increase sleep efficiency (p = .051) compared to stretching during the Treatment phase. Subjective sleep quality ratings did not differ between groups (p > .10). These preliminary findings suggest that moderate-intensity aerobic exercise may attenuate the sleep disturbances associated with cannabis withdrawal.]]> Tue 26 Jul 2022 09:52:23 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51187 Tue 09 Jan 2024 11:21:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54002 Thu 25 Jan 2024 13:53:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37568 Thu 18 Feb 2021 16:08:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52234 Thu 05 Oct 2023 11:39:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17227 Sat 24 Mar 2018 07:59:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23860 Sat 24 Mar 2018 07:12:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52509 Mon 16 Oct 2023 10:31:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50937 Mon 14 Aug 2023 12:58:13 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53522 18, and a treatment plan that included transfer from methadone to buprenorphine. Data were extracted on methadone dose, transfer medications, time to buprenorphine initiation, and transfer outcome. Interventions: Subjects were transferred via two methods: morphine bridged and nonbridged. Main outcome measure: The primary outcome measure was successful transition to buprenorphine. Results: Seventy-one subjects met inclusion criteria, of whom 62 initiated buprenorphine and 53 discharged on buprenorphine. Longer delay to buprenorphine initiation was seen with higher methadone doses. The highest daily methadone dose in subjects completing transfer was 180 mg. Outcomes with morphine bridging, using a steady state methadone: morphine ratio of 1:4, were similar to direct transfer. Only one subject discontinued buprenorphine because of PW. Conclusions: Transfer from high doses of methadone to buprenorphine can be achieved with high success rates in the in-patient setting.]]> Mon 04 Dec 2023 09:33:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23970 -1 (mean: 564 mg; 95% confidence interval 431-696 mg). Median buprenorphine dose was 12.0 mg (interquartile range 9.5 mg, range 4-32 mg) at day 7 and 16.0 mg (interquartile range 13.5 mg, range 4-32 mg) at day 28. Buprenorphine doses received were markedly higher than estimated codeine doses based on standard dose conversion tables.Discussion and Conclusions: With increasing presentations relating to codeine dependence, these findings provide important guidance to clinicians. Buprenorphine doses were consistently higher than doses estimated based on the dose of codeine consumed, and were comparable with doses used in the treatment of dependence with heroin and more potent prescription opioids.]]> Fri 01 Apr 2022 09:28:10 AEDT ]]>